Oncopeptides: Intends to File for Third Line - Redeye

Redeye provides a brief comment on Oncopeptides' decision to submit a type II variation to expand the Pepaxti label to include third-line treatment. Given this will take at least one year, it will not impact the near-term commercialisation of Pepaxti. It could increase the total addressable market long-term, however.

Länk till analysen i sin helhet: https://www.redeye.se/research/1166027/oncopeptides-intends-to-file-for-third-line?utm_source=finwire&utm_medium=RSS